UK-based GW Pharmaceuticals nets $29mm in US IPO
GW Pharmaceuticals PLC, UK developer of prescription cannabinoids, netted $29mm in its initial public offering in the US on the Nasdaq. As planned, it sold 3.5mm ADSs for $8.90. The company has been trading publicly on the London Stock Exchange’s AIM since June 2001.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.